IL165907A0 - N-substituted piperidine derivatives as serotonin receptor agents - Google Patents
N-substituted piperidine derivatives as serotonin receptor agentsInfo
- Publication number
- IL165907A0 IL165907A0 IL16590703A IL16590703A IL165907A0 IL 165907 A0 IL165907 A0 IL 165907A0 IL 16590703 A IL16590703 A IL 16590703A IL 16590703 A IL16590703 A IL 16590703A IL 165907 A0 IL165907 A0 IL 165907A0
- Authority
- IL
- Israel
- Prior art keywords
- serotonin receptor
- substituted piperidine
- piperidine derivatives
- receptor agents
- agents
- Prior art date
Links
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- -1 N-substituted piperidine Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39126902P | 2002-06-24 | 2002-06-24 | |
PCT/US2003/019797 WO2004000808A2 (fr) | 2002-06-24 | 2003-06-20 | Derives de piperidine substitues en n en tant qu'agents recepteurs de la serotonine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL165907A0 true IL165907A0 (en) | 2006-01-15 |
Family
ID=30000684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16590703A IL165907A0 (en) | 2002-06-24 | 2003-06-20 | N-substituted piperidine derivatives as serotonin receptor agents |
Country Status (15)
Country | Link |
---|---|
US (2) | US7476682B2 (fr) |
EP (1) | EP1562937A2 (fr) |
JP (1) | JP2005533813A (fr) |
KR (1) | KR20050008846A (fr) |
CN (2) | CN101619057A (fr) |
AU (1) | AU2003247615B2 (fr) |
BR (1) | BR0312217A (fr) |
CA (1) | CA2490397A1 (fr) |
HK (1) | HK1080842A1 (fr) |
IL (1) | IL165907A0 (fr) |
MX (1) | MXPA04012893A (fr) |
NZ (1) | NZ537522A (fr) |
RU (2) | RU2320646C2 (fr) |
WO (1) | WO2004000808A2 (fr) |
ZA (1) | ZA200410408B (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2397981C (fr) | 2000-03-06 | 2010-12-21 | Acadia Pharmaceuticals, Inc. | Composes azacycliques utilises dans le traitement de maladies liees a la serotonine |
WO2003057698A2 (fr) | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004000808A2 (fr) * | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | Derives de piperidine substitues en n en tant qu'agents recepteurs de la serotonine |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
KR101095939B1 (ko) | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2a/2c 리셉터 역작용제 |
ATE383335T1 (de) * | 2003-06-11 | 2008-01-15 | Lilly Co Eli | 3-amino-pyrrolidine als inhibitoren der monoamin- wiederaufnahme |
NZ544046A (en) * | 2003-06-17 | 2009-08-28 | Pfizer | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors |
WO2005053663A2 (fr) * | 2003-11-24 | 2005-06-16 | Eli Lilly And Company | Traitement de la defaillance cognitive |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
SG157378A1 (en) | 2004-09-27 | 2009-12-29 | Acadia Pharm Inc | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation |
US20090239929A1 (en) * | 2004-12-14 | 2009-09-24 | Paul Vincent Fish | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors |
CA2591415A1 (fr) * | 2004-12-16 | 2006-06-22 | Pfizer Limited | Nouveaux composes |
US20090036488A1 (en) * | 2005-03-04 | 2009-02-05 | Tokyo Medical And Dental University | Recurrence preventive therapeutic agent for psychostimulant-induced psychosis and schizophrenia |
WO2007136680A2 (fr) * | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Éthers, amines secondaires et leurs dérivés utilisés en tant que modulateurs des récepteurs 5-ht2a de la sérotonine et utiles pour traiter les troubles liés à ces récepteurs |
DK2134330T3 (da) | 2007-03-19 | 2013-08-05 | Acadia Pharm Inc | Kominationer af 5-ht2a-inverse agonister og antagonister med antipsykotika |
US8592435B2 (en) | 2007-04-27 | 2013-11-26 | Daiichi Sankyo Company, Limited | Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same |
EP2200610B1 (fr) * | 2007-09-21 | 2018-01-10 | Acadia Pharmaceuticals Inc. | Co-administration de pimavansérine avec d'autres agents |
CN101215274B (zh) * | 2007-12-27 | 2011-05-04 | 上海北卡医药技术有限公司 | N取代吗啉类有机化合物的制备工艺 |
PT3325444T (pt) | 2015-07-20 | 2021-09-22 | Acadia Pharm Inc | Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c |
CN105481844A (zh) * | 2015-12-08 | 2016-04-13 | 梁彦云 | 一种治疗高血压的药物组合物 |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (fr) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Association de pimavansérine et de modulateurs du cytochrome p450 |
CN105906551A (zh) * | 2016-04-27 | 2016-08-31 | 东南大学 | 5-ht2a反向激动剂acp-103的制备方法 |
EP3558311A1 (fr) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
EP3672960A2 (fr) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Composés, sels associés et méthodes de traitement de maladies |
CN111132976B (zh) | 2017-08-21 | 2023-08-22 | 阿卡蒂亚药品公司 | 化合物、其盐和用于治疗疾病的方法 |
EP3675827A1 (fr) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations de pimavansérine |
JPWO2021193790A1 (fr) * | 2020-03-26 | 2021-09-30 | ||
EP4186893A1 (fr) * | 2020-07-22 | 2023-05-31 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Inhibiteur du récepteur 5-ht2a ou agoniste inverse, procédé de préparation associé, et application associée |
WO2024067304A1 (fr) * | 2022-09-28 | 2024-04-04 | 瀚远医药有限公司 | Composé à activité inhibitrice contre sigma2 et 5ht2a et utilisation |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
GB1586468A (en) | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (fr) | 1978-04-03 | 1983-01-25 | Joseph Torremans | Nouvelles n-heterocycle-4-piperidinamines |
US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (fr) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Derives de l'uree et leur utilisation comme inhibiteurs de l'acat |
AU6971794A (en) | 1993-05-26 | 1994-12-20 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
US5707798A (en) * | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
NZ320963A (en) | 1995-09-29 | 1999-08-30 | Lilly Co Eli | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
CA2249601A1 (fr) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibiteurs de la farnesyl-proteine transferase |
AU2733997A (en) | 1996-04-17 | 1997-11-07 | Du Pont Pharmaceuticals Company | N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5877173A (en) | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
JP3310883B2 (ja) * | 1996-08-28 | 2002-08-05 | 三菱電機株式会社 | 移動体通信装置 |
EE04375B1 (et) | 1996-09-10 | 2004-10-15 | Dr. Karl Thomae Gmbh | Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
BR9808502A (pt) | 1997-05-08 | 2000-05-23 | Smithkline Beecham Corp | Inibidores de protease |
AU764766B2 (en) | 1998-04-14 | 2003-08-28 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
WO2000023076A1 (fr) | 1998-10-16 | 2000-04-27 | Suntory Limited | Derives d'acide aminophenoxyacetique comme neuroprotecteurs |
US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (fr) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalcanes comme modulateurs de CCR5 |
JP2002539260A (ja) | 1999-03-24 | 2002-11-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法 |
US6399619B1 (en) * | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
EP1183229B1 (fr) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Antagonistes/agonistes inverses de glucagon |
US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
CA2397981C (fr) | 2000-03-06 | 2010-12-21 | Acadia Pharmaceuticals, Inc. | Composes azacycliques utilises dans le traitement de maladies liees a la serotonine |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
WO2003057698A2 (fr) | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Composes spiroazacycliques utilises comme modulateurs du recepteur de monoamine |
EP1509505A2 (fr) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | Modulateurs a petites molecules du recepteur de serotonine 5-ht2a utiles pour la prophylaxie et le traitement de troubles associes |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
WO2004000808A2 (fr) | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | Derives de piperidine substitues en n en tant qu'agents recepteurs de la serotonine |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004009549A2 (fr) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines utiles pour traiter des maladies du systeme nerveux central |
AU2003284899A1 (en) | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
KR101095939B1 (ko) | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2a/2c 리셉터 역작용제 |
BRPI0406592A (pt) | 2003-01-23 | 2005-12-20 | Acadia Pharm Inc | Usos de n-desmetilclozapina, métodos para o tratamento de psicose, de distúrbios afetivos, de demência, de dor neuropática e de glaucoma e composição farmacêutica |
RU2330842C2 (ru) | 2003-02-17 | 2008-08-10 | Ф.Хоффманн-Ля Рош Аг | Производные пиперидинбензолсульфамида |
US7550454B2 (en) | 2003-12-22 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
KR100624421B1 (ko) * | 2004-05-04 | 2006-09-19 | 삼성전자주식회사 | 디지탈 영상 신호 필터링 장치 및 방법 |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
SG157378A1 (en) | 2004-09-27 | 2009-12-29 | Acadia Pharm Inc | Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation |
-
2003
- 2003-06-20 WO PCT/US2003/019797 patent/WO2004000808A2/fr active Application Filing
- 2003-06-20 MX MXPA04012893A patent/MXPA04012893A/es active IP Right Grant
- 2003-06-20 AU AU2003247615A patent/AU2003247615B2/en not_active Ceased
- 2003-06-20 RU RU2005101414/04A patent/RU2320646C2/ru not_active IP Right Cessation
- 2003-06-20 IL IL16590703A patent/IL165907A0/xx unknown
- 2003-06-20 CN CN200910136482A patent/CN101619057A/zh active Pending
- 2003-06-20 BR BR0312217-4A patent/BR0312217A/pt not_active IP Right Cessation
- 2003-06-20 JP JP2004516166A patent/JP2005533813A/ja active Pending
- 2003-06-20 EP EP03761275A patent/EP1562937A2/fr not_active Withdrawn
- 2003-06-20 CN CNB038188392A patent/CN100509804C/zh not_active Expired - Fee Related
- 2003-06-20 NZ NZ537522A patent/NZ537522A/en not_active IP Right Cessation
- 2003-06-20 KR KR10-2004-7020913A patent/KR20050008846A/ko not_active Application Discontinuation
- 2003-06-20 CA CA002490397A patent/CA2490397A1/fr not_active Abandoned
-
2004
- 2004-12-23 ZA ZA200410408A patent/ZA200410408B/xx unknown
-
2006
- 2006-01-16 HK HK06100687.2A patent/HK1080842A1/xx not_active IP Right Cessation
- 2006-05-03 US US11/417,866 patent/US7476682B2/en active Active
- 2006-05-03 US US11/418,353 patent/US20060205722A1/en not_active Abandoned
-
2007
- 2007-11-01 RU RU2007140675/04A patent/RU2007140675A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050008846A (ko) | 2005-01-21 |
US20060205722A1 (en) | 2006-09-14 |
NZ537522A (en) | 2006-07-28 |
AU2003247615A1 (en) | 2004-01-06 |
WO2004000808A2 (fr) | 2003-12-31 |
RU2320646C2 (ru) | 2008-03-27 |
HK1080842A1 (en) | 2006-05-04 |
CN100509804C (zh) | 2009-07-08 |
CA2490397A1 (fr) | 2003-12-31 |
US20060199818A1 (en) | 2006-09-07 |
CN1675201A (zh) | 2005-09-28 |
CN101619057A (zh) | 2010-01-06 |
BR0312217A (pt) | 2005-05-10 |
EP1562937A2 (fr) | 2005-08-17 |
AU2003247615B2 (en) | 2007-08-09 |
RU2007140675A (ru) | 2009-05-10 |
ZA200410408B (en) | 2005-09-22 |
US7476682B2 (en) | 2009-01-13 |
WO2004000808A3 (fr) | 2004-03-25 |
JP2005533813A (ja) | 2005-11-10 |
RU2005101414A (ru) | 2005-08-27 |
MXPA04012893A (es) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080842A1 (en) | N-substituted piperidine derivatives as serotonin receptor agents | |
HK1247610A1 (zh) | 作為nk1拮抗劑的哌啶衍生物 | |
IL165197A0 (en) | N-substituted tricyclic 3-aminopyrzoles as fdfg receptor inhibitors | |
PL375220A1 (en) | Piperidine derivatives | |
HK1072259A1 (en) | Indole derivatives useful as histamine h3 antagonists | |
HK1072251A1 (en) | Piperidine derivative | |
HK1073304A1 (en) | Triazole derivatives as tachykinin receptor antagonists | |
IL176014A0 (en) | Azepinoindole derivatives as pharmaceutical agents | |
NO20015365D0 (no) | Piperidinderivater som er anvendbare som CCR5-antagonister | |
IL195011A0 (en) | Process for preparing piperidine derivatives | |
GB0219896D0 (en) | Dihydropyridine derivatives | |
ZA200609225B (en) | Indole derivatives having piperidine rings | |
IL160060A0 (en) | Piperidine derivatives useful as ccr5 antagonists | |
IL171930A0 (en) | Imidazole derivatives as glutamate receptor antagonists | |
IL172542A0 (en) | 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide | |
AU2003275838A8 (en) | Pyrrolidin-2-on derivatives as ep4 receptor agonists | |
GB0314054D0 (en) | Amide derivatives as selective serotonin re-uptake inhibitors | |
IL164016A0 (en) | Azetidine derivatives as ccr-3 receptor antagonists | |
IL144299A0 (en) | N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists | |
AU2002347552A1 (en) | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists | |
AU2003251627A8 (en) | Carvedilol hydrobromide | |
EP1538142A4 (fr) | Derive d'amine | |
AU2003256862A8 (en) | Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands | |
GB0220962D0 (en) | Heterocyclic derivatives | |
ZA200409554B (en) | Heterocyclic derivatives as opioid modulators |